Study says: Certain OTC eardrops may result in hearing loss or damage
Study finds that certain OTC eardrops may cause hearing loss or damage
New products: January 28, 2008
New branded prescription drugs, new formulations, new indications, generics, OTCs, etc.
OTC allergy drugmakers are ready to battle for consumers
OTC allergy drug battle heats up
Study: Women's use of supplements is down
Women's supplement usage declining
Survey says: Americans lack knowledge about nutrition, multivitamins
Survey reveals Americans are uneducated about nutrition, multivitamins
FDA: OTC cough and cold products should not be used in those under two
Do not use OTC cough and cold products among infants and children under two years of age
Survey: Supplement use higher among Republicans than Democrats
Republicans are more likely to used vitamin supplement than Democrats
New remedies just in time for cough and cold onslaught
Manufacturers are unleashing a slew of cough and cold over the counter items.
2007 Drug Topics OTC Cough, Cold, and Flu survey
What OTCs do R.Ph.s recommend for cough & cold season?
Revised SOM guide for surveyors bolstering role of consultant R.Ph.s
Consultant pharmacists applaud CMS' guidelines on nursing home surveyors one year after State Operations Manual guidelines become effective.
New products: January 14, 2008
Coverage of branded drugs, new indications, new formulations, new dosages, along with OTCs.
Featuring this month: Cough and cold medications
Drug Topics conducted an exclusive OTC survey for cough, cold and flu products.
OTC asthma inhalers: Worthy of more time on market?
FDA is considering how to deal with the phaseout of chlorofluorocarbons from inhalers, which is only a year away.
SAMHSA study: OTC cough and cold medications abused by 12- to 25-year-olds
SAMHSA: 3.1 million young adults have abused OTC cough medicine in their lifetime.
Drug Topics OTC Cold, Cough, and Flu Survey, December, 2007
Drug Topics survey: R.Ph.s give thumbs down to Mevacor OTC
Drug Topics' poll finds pharmacists against Mevacor going OTC.
FDA to consumers: Don't take supplements for ED, sexual enhancement
FDA issues warning on supplements marketed for ED, sexual enhancement
Bill to restrict access to DHEA introduced
Legislation introduced to restrict access to DHEA
FDA's final rule requires warning for nonoxynol 9 OTC contraceptives
FDA's final rule mandates warning for nonoxynol 9 OTC contraceptives
CHPA issues statement on FDA's recommendations on phenylephrine
CHPA supports FDA's recommendations on phenylephrine
Natural Products Association comments on MLB's Mitchell Report
Natural Products Association responds to MLB's Mitchell Report
CHPA applauds NIDA's cough medicine abuse monitoring survey
CHPA responds to NIDA's cough medicine abuse monitoring survey
FDA advisory panel rejects OTC status for Merck's Mevacor
FDA advisory panel rejects Merck's bid for OTC Mevacor
Drug Topics survey finds R.Ph.s approve of BTC class of drugs
Drug Topics poll: R.Ph.s favor BTC class of drugs
CRN calls for transparency in testing dietary supplements
CRN responds to Informed-Choice report calling for transparency in testing dietary supplements
This breast cancer drug is first in new class of chemo agents
The FDA has approved Ixabepilone (Ixempra) as a monotherapy and in combination with capecitabine (Xeloda) for patients with metastic or locally advanced breast cancer.
New products: December 10, 2007
The new products include branded drugs, new formulations, new indications, and new dosing, along with OTCs and home health and beauty items.
FDA hears mixed views on third class of drugs
Pharmacists' organizations were out in force at a recent FDA hearing on the possibility of creating a third category of drugs that would be placed "behind-the-counter" and pharmacist-assisted.
Alli and Byetta affecting obesity market
Rxs for Xenical down since OTC Alli released
Democrats urge FDA to test lipstick for lead
Sens. John Kerry, Diane Feinstein, and Barbara Boxer urge the FDA to test lipstick for lead
